COMMUNIQUÉS West-GlobeNewswire

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
27/02/2026
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease [...]
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
27/02/2026
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first targeted medicine in [...]
Flare Therapeutics Presents Updated FX-909 Phase 1A Data in Late-Breaking Oral Presentation at 2026 ASCO Genitourinary Cancers Symposium
27/02/2026
Data support emergence of differentiating clinical benefit with a favorable safety and tolerability profile for patients with advanced UC CAMBRIDGE, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. ( [...]
Communiqué de presse: L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil
27/02/2026
L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil La recommandation s’appuie [...]
Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
27/02/2026
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of [...]
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
27/02/2026
Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety [...]
Orion Group Financial Statement documents 2025 and Remuneration Report published
27/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 27 FEBRUARY 2026 at 11.05 EET Orion Group Financial Statement documents 2025 and Remuneration Report published Orion Group's Financial Statement [...]
Trading by management and close relations of management
27/02/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
ICPO and UroTeragLATAM signed a strategic agreement to accelerate Theranostics for urological cancer in Latin America
27/02/2026
The partnership strengthens education, innovation, and patient access by combining global expertise with regional leadership in precision oncology. February 27, 2026 – Wiesbaden, Germany and Miami, USA. The [...]
Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
27/02/2026
Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge ( [...]
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
27/02/2026
Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE® (vamorolone), in the [...]
Herz P1 Smart Band 2026: What It Tracks, How It Works, and What Consumers Should Know Before Buying
27/02/2026
A 2026 Informational Overview of the Herz P1 Smart Band's Subscription-Free Health Monitoring Features, Heart Rate and HRV Tracking, Sleep Quality Analysis, Blood Oxygen and SpO2 Sensors, Stress and Temperature [...]
QuickBurn BHB 2026: What Consumers Should Know About BHB Ketone Supplements Before Buying
27/02/2026
An informational overview of the QuickBurn BHB exogenous ketone supplement — ingredients, BHB salt research, potential side effects, ketosis claims, and what to verify before ordering. Largo, FL, Feb. 26, 2026 (GLOBE [...]
BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
26/02/2026
CHENGDU, China, Feb. 26, 2026 (GLOBE NEWSWIRE) -- BGM Group Ltd. (NASDAQ: BGM) (the “Company” or “BGM”) announced on February 24, 2026, that it has received a notification (the “Notification”) from the Listing [...]
Inventiva to Participate in Four Upcoming March Investor Conferences
26/02/2026
Daix (France), New York (United States), February 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral [...]
The Kidney Foundation of Canada highlights need for Canadians to act on kidney health
26/02/2026
Take Action This Kidney Health Month and Ahead of World Kidney Day 2026 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- As Kidney Health Month gets underway, The Kidney Foundation of Canada is calling on Canadians to take [...]
La Fondation canadienne du rein souligne la nécessité pour les Canadiens d'agir pour leur santé rénale
26/02/2026
Agissez pendant ce Mois de la santé rénale et à l'approche de la Journée mondiale du rein 2026 MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Alors que le Mois de la santé rénale débute, La Fondation canadienne du rein [...]
Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
Inventiva participera à quatre conférences investisseurs en mars
26/02/2026
Daix (France), New York ( États-Unis ), le 26 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie [...]

Pages